Ask most women over 40 what they worry about most health-wise in menopause and they will say breast cancer. That fear is understandable given how much cultural attention it receives. But statistically, the larger threat is the one that receives far less attention, the one that accounts for nearly half of all deaths in women over 50. Cardiovascular disease kills more women than all cancers combined, and the menopausal transition is a direct accelerant of cardiovascular risk in ways that most women have never been told.

This is not an argument to stop thinking about breast cancer. It is an argument for equal attention to the risk that is more likely to kill you, one that is also significantly modifiable with the right knowledge and the right interventions at the right time.

This article will explain exactly what estrogen does for the cardiovascular system, how the menopausal transition changes your risk profile, what the SWAN study found about specific cardiovascular markers, and what the evidence says about the most effective strategies for protecting your heart in midlife and beyond.

Estrogen and the cardiovascular system

Estrogen has wide-ranging effects on cardiovascular health, many of which only become apparent when it declines. It promotes vasodilation (relaxation of blood vessels), reduces arterial stiffness, supports healthy cholesterol ratios by raising HDL and lowering LDL, improves insulin sensitivity, reduces inflammatory markers, and has antioxidant effects in arterial walls.

When estrogen levels decline during perimenopause, all of those cardioprotective mechanisms weaken simultaneously. The result is a shift in cardiovascular risk profile that is measurable, meaningful, and often begins years before the final menstrual period.

According to the American Heart Association, cardiovascular disease is the leading cause of death in women over 50 in the United States. The disparity between how seriously this risk is communicated to women and how seriously breast cancer risk is communicated to women is striking and consequential. Women who prioritize every breast screening but have never had their blood pressure, fasting glucose, or lipid panel discussed in the context of menopause are operating with an incomplete picture of their actual health risks.

What the SWAN study found

The Study of Women’s Health Across the Nation (SWAN), a landmark longitudinal study following over 3,000 women across multiple ethnic and racial backgrounds over more than twenty years, has produced some of the most important data on cardiovascular changes during the menopausal transition.

SWAN found that cardiovascular risk markers change meaningfully during the transition. LDL cholesterol rises significantly in the late perimenopause and early postmenopause period, by an average of around 10-14 mg/dL. HDL levels may also shift. Blood pressure tends to increase. Markers of insulin resistance increase during the transition. Subclinical atherosclerosis, the buildup of plaque in arterial walls before any clinical symptoms develop, progresses faster in women who enter menopause earlier and in women with more severe vasomotor symptoms.

The SWAN study also found that visceral fat accumulation, the metabolically active fat that accumulates around the abdominal organs, increases during the menopausal transition in ways that are not fully explained by aging or caloric intake changes alone. Visceral fat is directly linked to insulin resistance, inflammation, and cardiovascular risk.

These findings matter because they identify the perimenopause years as a critical window for cardiovascular risk management, not just a time when symptoms need to be managed.

The specific risks that increase at menopause

Several specific cardiovascular risk factors become particularly important to monitor and address during and after the menopausal transition.

Blood pressure changes significantly. Pre-menopausal women have lower average blood pressure than age-matched men, partly due to estrogen’s vasodilatory effects. This advantage largely disappears after menopause. Women who enter menopause with borderline blood pressure often see it rise into hypertensive range within a few years of the transition. Hypertension is the single most significant modifiable cardiovascular risk factor.

Cholesterol and lipid profile changes. LDL rises, and the particle size of LDL may shift toward the smaller, denser particles that are associated with higher cardiovascular risk. Triglycerides often increase. These changes happen relatively quickly and make the years around menopause an important time for a full lipid panel.

Insulin resistance and blood sugar regulation. Estrogen supports insulin sensitivity. With its decline, fasting blood glucose, fasting insulin, and HbA1c (a marker of average blood sugar) tend to worsen. This creates a trajectory toward prediabetes and type 2 diabetes that significantly compounds cardiovascular risk.

Chronic inflammation. C-reactive protein, a marker of systemic inflammation, tends to increase in postmenopausal women. Chronic low-grade inflammation is central to atherosclerotic plaque development.

The timing hypothesis: HRT and cardiovascular protection

The research on HRT and cardiovascular health is one of the most important and most misunderstood areas in menopause medicine. The “timing hypothesis” suggests that HRT initiated close to menopause onset has cardioprotective effects, while HRT initiated much later may not carry the same benefits.

The WHI study, which found increased cardiovascular events in some HRT users, enrolled women with a mean age of 63. Subsequent analysis revealed that the women who showed increased risk were predominantly more than ten years past menopause and had pre-existing subclinical cardiovascular disease. Women who enrolled in the study within ten years of menopause and did not have pre-existing cardiovascular disease did not show the same increased risk profile, and in some analyses showed reduced cardiovascular events.

The ELITE trial (Early versus Late Intervention Trial with Estradiol) directly tested this hypothesis. Women randomized to estradiol therapy within six years of menopause showed significantly less progression of subclinical atherosclerosis (measured by carotid intima-media thickness) compared to placebo, while women who started estradiol more than ten years after menopause did not show the same benefit. This supports the view that the window for cardiovascular benefit from HRT is real and time-limited.

What you can do now

Whether or not HRT is part of your plan, the lifestyle evidence for cardiovascular protection in menopause is clear and starts immediately.

Resistance training improves insulin sensitivity, reduces visceral fat, lowers blood pressure, and improves lipid profiles. Cardiovascular exercise, particularly aerobic work in zone 2 (moderate intensity, sustainable for extended periods), directly supports heart health, endurance, and arterial elasticity. According to the American Heart Association, women who engage in 150 minutes of moderate-intensity aerobic activity per week have significantly lower cardiovascular mortality risk.

Dietary quality matters significantly. A Mediterranean-style diet reduces LDL, reduces inflammatory markers, and is associated with lower cardiovascular mortality in multiple large trials including PREDIMED. Reducing ultra-processed food, prioritizing fiber, healthy fats, and lean protein, and moderating alcohol are all evidence-backed steps.

Monitoring matters. Blood pressure, fasting glucose, HbA1c, and a full lipid panel should be part of your regular health monitoring from perimenopause onward. These are not optional extras. They are your early warning system.

Sleep and stress management complete the picture. Chronic sleep deprivation and chronic psychological stress both increase cortisol, inflammatory markers, and blood pressure in ways that directly compound cardiovascular risk. Treating menopause-related sleep disruption is therefore a cardiovascular health strategy.

Your heart is the organ that has to keep working for another four, five, six decades. The transition you are in right now changes its risk environment. Knowing that is the beginning of protecting it.

Medical disclaimer: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding any medical condition or before starting any new treatment.